Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761257 | 0.87 | NOD2 (0.40) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL1316576 | 0.83 | NOD2 (0.38) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5223527 | 0.83 | NOD2 (0.36) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL4598165 | 0.81 | NOD2 (0.44) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5222402 | 0.81 | NOD2 (0.35) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL31095788 | 0.80 | NOD2 (0.45) | NOD2NOD1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5220266 | 0.79 | NOD2 (0.37) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5217796 | 0.78 | KMT2A (0.40) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5220157 | 0.78 | NOD2 (0.36) | NOD2NOD1ADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL33376850 | 0.78 | NOD2 (0.38) | NOD2NOD1ADORA3SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | claimed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | claimed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| CN-100400538-C | 5HT for the treatment of diabetes and obesity2cReceptor agonists | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1641796-B1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1290847-C | Aza-aryl piperazines | HOFFMANN LA ROCHE (CH) | 2006-12-20 | — | — | CN | disclosed |
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| CN-1812989-A | 5ht2c receptor agonists for the treatment of diabetes and obesity | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
| EP-1641796-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| EP-1472255-B1 | AZA-ARYLPIPERAZINES | HOFFMANN LA ROCHE (CH) | 2006-03-01 | — | — | EP | disclosed |
| CN-1625558-A | Aza-arylpiperazines | HOFFMANN LA ROCHE (CH) | 2005-06-08 | — | — | CN | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, IDO1 | NOD2 3122/4885NOD1 3488/4885ADORA3 235/4885 |
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | NOD2 1825/4885NOD1 281/4885ADORA3 1039/4885 |
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | NOD2 2274/4885NOD1 2471/4885ADORA3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.